pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,361 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1774Endpoints1383Fierce Biotech702BioSpace694BioPharma Dive523raps231onclive165fda recalls111
therapy area
allOncology12291Rare Disease3188Immunology2860Cardiology2725Hematology2167Pulmonology2136Vaccines
  • LifeMine Therapeutics secures $188 million Series E funding from Gates, Bezos and others
    LifeMine Therapeutics, a Massachusetts biotech, recently completed a $188 million Series E round, attracting billionaire investors Bill Gates and Jeff Bezos. The funding follows a $75 million Seri…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • Novo Nordisk looks to bolt-on acquisitions as pipeline setbacks mount
    Novo Nordisk CEO Maziar Mike Doustdar said on a media call that the pharma industry is tough for those who dislike setbacks and failure. He highlighted recent disappointments in the company's pipe…
    Endpoints · 3mo agoDealNeutral↗ source
← prev
page 56 of 95
next →
fda medwatch109
globenewswire health73
fda press59
1794
Psychiatry & CNS1200
Ophthalmology1049
Endocrinology & Metabolism775
Pain773
Nephrology759
  • Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debut
    Attovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million. The funds will support the development of three I&I dru…
    Endpoints · 3mo agoDealPositive↗ source
  • Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecasts
    Gilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter. This figure exceeds analysts' consensus estimat…
    Endpoints · 3mo agoEarningsPositive↗ source
  • Emergent BioSolutions cuts 93 jobs and eliminates chief medical officer role in new restructuring plan
    Emergent BioSolutions announced a new round of restructuring aimed at aligning the company with current business realities, disclosed alongside its second‑quarter earnings. The plan includes layin…
    Fierce Biotech · 3mo agoLayoffsNegative↗ source
  • Arrowhead Pharma to pay $215 million for PRV in its latest acquisition
    Arrowhead Pharmaceuticals disclosed in an SEC filing that it will acquire PRV for $215 million, marking the highest price tag for a deal this year. The purchase aligns with Arrowhead's strategy of…
    Endpoints · 3mo agoDealNeutral↗ source
  • Expedition Therapeutics raises $115M Series B for China-sourced COPD candidate
    Expedition Therapeutics, a US biotech, announced a $115 million Series B financing round. The capital will be used to advance its COPD drug candidate that is being developed from a China-sourced p…
    Endpoints · 3mo agoDealPositive↗ source
  • Fecal microbiome transplant boosts peanut tolerance sixfold in early trial
    Researchers at Boston Children’s Hospital conducted a small open‑label phase 1 trial in which 15 adult participants received oral encapsulated fecal microbiome transplantation to test safety and ef…
    Fierce Biotech · 3mo agoPositive readoutPositive↗ source
  • Novo Nordisk CFO describes roller-coaster growth and stays optimistic about CagriSema after Q2 earnings
    Novo Nordisk CFO Karsten Munk Knudsen talked to Fierce after the company released its second-quarter earnings, reflecting on his nine-year tenure and the firm’s volatile performance. He recalled a…
    Fierce Biotech · 3mo agoEarningsNeutral↗ source
  • Attovia Therapeutics raises $289 million in IPO to fund anti-itch drug development
    Attovia Therapeutics completed an initial public offering that generated $289 million in gross proceeds. The company sold 17 million shares at $17 each, exceeding its original target of $182.4 mill…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • WuXi AppTec posts six-month revenue higher than Lonza for first time
    WuXi AppTec, a Chinese contract manufacturing organization, has reported that its revenue over the most recent six-month period exceeded that of Swiss CDMO Lonza for the first time. The increase c…
    Endpoints · 3mo agoPositive↗ source
  • Sanofi pauses phase 2 bronchiectasis trial of SAR445399 for strategic reasons
    Sanofi has halted a phase 2 study of its monoclonal antibody SAR445399 in adults with non‑cystic fibrosis bronchiectasis. The trial, which began in April, was a randomized, double‑blind, placebo‑co…
    Fierce Biotech · 3mo agoNegative↗ source
  • AstraZeneca and Bristol Myers Squibb abandon merger talks
    Reuters reported that AstraZeneca and Bristol Myers Squibb have ended discussions about a possible merger and will not pursue a deal. The collapse of the talks removes a potential consolidation th…
    Endpoints · 3mo agoDealNegative↗ source
  • Eli Lilly removes Gaucher disease gene therapy trial from pipeline, citing unmet internal criteria
    Eli Lilly has announced the removal of a phase 1/2 study testing its GBA1 gene therapy for Gaucher disease type 1. The program was part of the assets acquired when the company bought Prevail Therap…
    Fierce Biotech · 3mo agoNegative readoutNegative↗ source
  • Senate confirms Erica Schwartz as new CDC director
    The U.S. Senate voted 51 to 44 on Wednesday to confirm Erica Schwartz as the next director of the Centers for Disease Control and Prevention. Schwartz, a former deputy surgeon general and a vetera…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Atossa Therapeutics CEO Steven Quay likely to become NIAID director
    Steven Quay, founder and CEO of Atossa Therapeutics, is reported to be the likely choice for director of NIH's National Institute of Allergy and Infectious Diseases. The report notes his backgroun…
    Endpoints · 3mo agoNeutral↗ source
  • Fujifilm Biotechnologies appoints COO Maja Pedersen as new president after Lars Petersen steps down
    Fujifilm Biotechnologies announced that its chief executive officer and president, Lars Petersen, has stepped down effective immediately. The company said the transition will be seamless as the cur…
    Endpoints · 3mo agoNeutral↗ source
  • Alphabet reshuffles AI leadership as DeepMind CEO steps down to become chief scientist
    Alphabet announced a reorganization of its artificial intelligence leadership. Demis Hassabis will leave his role as chief executive of Google DeepMind and take on the position of chief scientist f…
    Endpoints · 3mo agoNeutral↗ source
  • Sun Noodle voluntarily recalls 134 packages of Sura Tanmen hot and sour noodles in Hawaii over undeclared fish allergen
    Sun Noodle of Honolulu announced a voluntary recall of its Sura Tanmen Hot and Sour Flavor Premium Japanese Noodles & Soup Base. The recall covers 134 packages, each 15.4 ounces, identified by lot…
    fda recalls · 3mo agoCRLNegative↗ source
  • Pathos AI acquires bispecific ADC from Alphamab and secures AstraZeneca partnership
    Pathos AI announced it will pay $125 million upfront for the rights to JSKN016, a bispecific TROP2/HER3 antibody‑drug conjugate from China’s Alphamab Oncology. The agreement also includes up to $2.…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • Otsuka's Voyxact hits key secondary endpoint in Phase 3 IgA nephropathy trial as BioNTech cuts revenue outlook
    Otsuka announced that its experimental kidney drug Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study of patients with IgA nephropathy. The positive result suggests the therapy ha…
    Endpoints · 3mo agoPositive readoutNeutral↗ source
  • Amgen halts development of early-stage obesity drug AMG 513, shifting focus to phase-3 candidate MariTide
    Amgen announced it is stopping work on AMG 513, an early-stage obesity therapy, during its second-quarter earnings call. The decision follows a previous FDA clinical hold in early 2025 that was la…
    Fierce Biotech · 3mo agoNegative↗ source
  • Expedition Therapeutics raises $115M Series B to fund phase 2 COPD trial of DPP1 inhibitor
    Expedition Therapeutics, backed by Sanofi, announced a $115 million Series B financing round. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, and existing i…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • Lisata cuts 72% of workforce and sues Kuva after merger collapse
    Lisata, a solid tumor biotech, announced it is laying off roughly 72% of its employees, including its chief medical officer, as it reassesses its future. The cuts follow the collapse of a planned…
    Fierce Biotech · 3mo agoLayoffsNegative↗ source
  • Merck’s anti‑TL1A antibody misses SSc‑ILD trial but hits primary endpoints in hidradenitis suppurativa
    Merck's anti‑TL1A monoclonal antibody, tulisokibart, was evaluated in two phase 2 studies. In the systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) trial, the primary endpoint was…
    Fierce Biotech · 3mo agoNeutral↗ source